Validation of the Screen of Cancer Survivorship - Occupational Therapy Services (SOCS-OTS) Tool for Use in a Physical Medicine Rehabilitation Clinic

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06329531

Enrollment

Registered

2024-03-26

Start date

2024-07-12

Completion date

2027-12-01

Last updated

2026-04-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Occupational Therapy

Brief summary

To compare the results of the SOCS-OTS to another standardized screening measure that is currently being used by rehabilitation services at MD Anderson Cancer Center and to ensure that the SOCS-OTS correctly identifies those individuals needing OT services in cancer care.

Detailed description

Primary Aim 1\. Explore the SOCS-OTS for use in the Physical Medicine and Rehabilitation (PM&R) clinic by means of diagnostic testing including sensitivity and specificity. Secondary Aims 1. Explore whether the SOCS-OTS identifies the likelihood that the presence or absence of OT referral is correctly predicted. To accomplish this, the likelihood ratios, and predictive values of the SOCS-OTS will be assessed. 2. Determine associations between the need for OT and demographic factors such as stage of cancer, cancer treatment etc. 3. Establish test-retest reliability of the SOCS-OTS.

Interventions

OTHERScreen of Cancer Survivorship - Occupational Therapy Services (SOCS-OTS)

Given by Questionnaire

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Must be 18 years an older 2. Currently medically followed in the PMR clinic (with or without acute disease) 3. Must speak and read English. The AM-PAC is currently validated in adults only. Additionally, the assessment tools are in English without translation into other languages, therefore only clients who do speak and read English will be included. Pregnant participants are not excluded.

Exclusion criteria

1\. Potential participants with confusion and cognitive impairments that might hinder their ability to sign an informed consent form or participate in the study.

Design outcomes

Primary

Measure	Time frame	Description
Safety and adverse events (AEs)	Through study completion; an average of 1 year.	Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)

Countries

United States

Contacts

CONTACTEkta Gupta, MD

egupta@mdanderson.org(713) 745-2327

PRINCIPAL_INVESTIGATOREkta Gupta, MD

M.D. Anderson Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 17, 2026